BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31891230)

  • 21. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
    Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
    J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP
    Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
    Meng W; Meng J; Zhang F; Jiang H; Feng X; Zhao F; Wang K
    J Physiol Pharmacol; 2021 Oct; 72(5):. PubMed ID: 35158336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Zhang L; Li J; Hu J; Li D; Wang X; Zhang R; Zhang H; Shi M; Chen H
    Lung Cancer; 2017 Jul; 109():109-116. PubMed ID: 28577939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
    Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells.
    Ting CH; Chen JY
    Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30551662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
    Pan C; Duan H; Wu Y; Zhu C; Yi C; Duan Y; Lu D; Guo C; Wu D; Wang Y; Fu X; Xu J; Chen Y; Luo M; Tian W; Pan T; Xu W; Zhang S; Huang J
    Int J Oncol; 2020 Oct; 57(4):939-955. PubMed ID: 32945394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway.
    Wen C; Li Y; Huang Y; Wang N; He S; Bao M; Zhou H; Wu L
    Int J Biochem Cell Biol; 2023 Jan; 154():106344. PubMed ID: 36503048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
    Wang H; Fei Z; Jiang H
    J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
    Tong CWS; Wu MMX; Yan VW; Cho WCS; To KKW
    Cancer Treat Res Commun; 2020; 25():100229. PubMed ID: 33152554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
    Chen Y; Zhang C; Jin S; Li J; Dai J; Zhang Z; Guo R
    J Cell Mol Med; 2023 Jul; 27(14):2032-2044. PubMed ID: 37278440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
    La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
    J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
    J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
    Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
    Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.